TY - JOUR
T1 - Services and prevention
T2 - Pharmacoepidemiology of antidepressant use
AU - Zito, Julie Magno
AU - Safer, Daniel J.
N1 - Funding Information:
Aspects of this work were presented at the conference, “The Unmet Needs in Diagnosis and Treatment of Mood Disorders in Children and Adolescents,” October 17–18, 2000, in Washington, DC. The conference was sponsored by the National Depressive and Manic-Depressive Association through unrestricted educational grants provided by Abbott Laboratories, AstraZeneca, Bristol-Meyers Squibb Company, Forest Laboratories Inc., Glaxo Wellcome Inc., The Henry Foundation, Janssen Pharmaceutica, Eli Lilly and Company, Merck & Co. Inc., National Institute of Mental Health, Pfizer Inc., Pharmacia, SmithKline Beecham, Solvay Pharmaceuticals Inc., and Wyeth-Ayerst Laboratories.
PY - 2001/6/15
Y1 - 2001/6/15
N2 - Between 1988 and 1994, data from 3 large sites revealed a 3-5 fold increase in the prevalence of antidepressant (ATD) treatment for U.S. youths aged 2-19 years. In 1994, the ATD prevalence for youths of this age ranged from 13 per 1000 (in the HMO) to 18 per 1000 (in 2 state Medicaid systems). Males predominated in the 10-14-year-olds treated with ATDs, whereas females predominated among 15-19-year-olds. Caucasians were more than twice as likely to receive ATD therapy than their African-American counterparts. Primary care providers were the major source of ATD prescriptions for youths. The leading diagnoses in primary care were ADHD followed by depression, whereas the diagnostic order was reversed for youths who received psychiatric services. This review provides details concerning these patterns and trends in ATD treatment of youths from community-based clinical data sources. In addition, the role of these data in an expanded, comprehensive psychotropic knowledge base is discussed. Finally, the implications of an expanded knowledge base for ATD treatments are discussed in regard to generating research questions on effectiveness and safety and to improve treatment consensus within a public-health perspective.
AB - Between 1988 and 1994, data from 3 large sites revealed a 3-5 fold increase in the prevalence of antidepressant (ATD) treatment for U.S. youths aged 2-19 years. In 1994, the ATD prevalence for youths of this age ranged from 13 per 1000 (in the HMO) to 18 per 1000 (in 2 state Medicaid systems). Males predominated in the 10-14-year-olds treated with ATDs, whereas females predominated among 15-19-year-olds. Caucasians were more than twice as likely to receive ATD therapy than their African-American counterparts. Primary care providers were the major source of ATD prescriptions for youths. The leading diagnoses in primary care were ADHD followed by depression, whereas the diagnostic order was reversed for youths who received psychiatric services. This review provides details concerning these patterns and trends in ATD treatment of youths from community-based clinical data sources. In addition, the role of these data in an expanded, comprehensive psychotropic knowledge base is discussed. Finally, the implications of an expanded knowledge base for ATD treatments are discussed in regard to generating research questions on effectiveness and safety and to improve treatment consensus within a public-health perspective.
KW - Antidepressants
KW - Child and adolescent psychopharmacology
KW - Consensus development
KW - Mental health services
KW - Pharmacoepidemiology
UR - http://www.scopus.com/inward/record.url?scp=0035875148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035875148&partnerID=8YFLogxK
U2 - 10.1016/S0006-3223(01)01174-X
DO - 10.1016/S0006-3223(01)01174-X
M3 - Review article
C2 - 11430854
AN - SCOPUS:0035875148
SN - 0006-3223
VL - 49
SP - 1121
EP - 1127
JO - Biological psychiatry
JF - Biological psychiatry
IS - 12
ER -